- Home
- Publications
- Publication Search
- Publication Details
Title
Prospects of Immunotherapy for Triple-Negative Breast Cancer
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-01-17
DOI
10.3389/fonc.2021.797092
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- LBA16 KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC
- (2021) J. Cortés et al. ANNALS OF ONCOLOGY
- Cocktail strategy for ‘cold’ tumors therapy via active recruitment of CD8+ T cells and enhancing their function
- (2021) Xiang Li et al. JOURNAL OF CONTROLLED RELEASE
- Oncolytic adenovirus targeting TGF-β enhances anti-tumor responses of mesothelin-targeted chimeric antigen receptor T cell therapy against breast cancer
- (2020) Yuxiang Li et al. CELLULAR IMMUNOLOGY
- Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment
- (2020) Tina Krieger et al. Diagnostic Pathology
- Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer
- (2020) Zhiwei Hu Scientific Reports
- Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer
- (2020) Ami N Shah et al. Journal for ImmunoTherapy of Cancer
- Tumoral PD-1hiCD8+ T cells are partially exhausted and predict favorable outcome in triple-negative breast cancer
- (2020) Liang Guo et al. CLINICAL SCIENCE
- KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.
- (2020) Javier Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Role of Immunotherapy in Triple-Negative Breast Cancer
- (2020) Tanya E. Keenan et al. Journal of the National Comprehensive Cancer Network
- Evaluation of glucocorticoid-induced TNF receptor (GITR) expression in breast cancer and across multiple tumor types
- (2020) Mayanne M. T. Zhu et al. MODERN PATHOLOGY
- Oncolytic vesicular stomatitis virus–based cellular vaccine improves triple-negative breast cancer outcome by enhancing natural killer and CD8+T-cell functionality
- (2020) Seyedeh-Raheleh Niavarani et al. Journal for ImmunoTherapy of Cancer
- Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial
- (2020) Jieqiong Liu et al. Journal for ImmunoTherapy of Cancer
- Tumor-Infiltrating CD8 T Cells Predict Clinical Breast Cancer Outcomes in Young Women
- (2020) Yong Won Jin et al. Cancers
- Oncolytic Herpes Simplex Virus Encoding IL12 Controls Triple-Negative Breast Cancer Growth and Metastasis
- (2020) Shanawaz M. Ghouse et al. Frontiers in Oncology
- Loss of the proprotein convertase Furin in T cells represses mammary tumorigenesis in oncogene-driven triple negative breast cancer
- (2020) Zongsheng He et al. CANCER LETTERS
- Targeting epidermal growth factor‐overexpressing triple‐negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor
- (2020) Yan Liu et al. CELL PROLIFERATION
- Efficacy of co-immunization with the DNA and peptide vaccines containing SYCP1 and ACRBP epitopes in a murine triple-negative breast cancer model
- (2020) Ashkan Safavi et al. Human Vaccines & Immunotherapeutics
- Tumor membrane-based vaccine immunotherapy in combination with anti-CTLA-4 antibody confers protection against immune checkpoint resistant murine triple-negative breast cancer
- (2020) Christopher D. Pack et al. Human Vaccines & Immunotherapeutics
- Biological Landscape of Triple Negative Breast Cancers Expressing CTLA-4
- (2020) María G. C. Navarrete-Bernal et al. Frontiers in Oncology
- A Structurally Simple Vaccine Candidate Reduces Progression and Dissemination of Triple-Negative Breast Cancer
- (2020) Amedeo Amedei et al. iScience
- Emerging CAR-T Cell Therapy for the Treatment of Triple Negative Breast Cancer
- (2020) Sundee Dees et al. MOLECULAR CANCER THERAPEUTICS
- Circulating microRNAs and their role in the immune response in triple‑negative breast cancer (Review)
- (2020) Patricia Piña‑Sánchez et al. Oncology Letters
- Intercellular Adhesion Molecule-1 as Target for CAR-T-Cell Therapy of Triple-Negative Breast Cancer
- (2020) Heng Wei et al. Frontiers in Immunology
- Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies
- (2020) Gagan K. Gupta et al. Cancers
- Targeting the Id1-Kif11 Axis in Triple-Negative Breast Cancer Using Combination Therapy
- (2020) Archana P. Thankamony et al. Biomolecules
- Enhancing anti-tumour efficacy with immunotherapy combinations
- (2020) Funda Meric-Bernstam et al. LANCET
- MALAT-1: LncRNA ruling miR-182/PIG-C/mesothelin triad in triple negative breast cancer
- (2020) Farida S. Barsoum et al. PATHOLOGY RESEARCH AND PRACTICE
- Recombinant SLAMblind Measles Virus Is a Promising Candidate for Nectin-4-Positive Triple Negative Breast Cancer Therapy
- (2020) Tomoko Fujiyuki et al. Molecular Therapy-Oncolytics
- Infiltration of CD8+ T cells into tumor cell clusters in triple-negative breast cancer
- (2019) Xuefei Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers
- (2019) Tina Gruosso et al. JOURNAL OF CLINICAL INVESTIGATION
- Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies
- (2019) Yi-Zhou Jiang et al. CANCER CELL
- Expression of PD-L1 Attenuates the Positive Impacts of High-level Tumor-infiltrating Lymphocytes on Prognosis of Triple-negative Breast Cancer
- (2019) Xudong Zhu et al. CANCER BIOLOGY & THERAPY
- Radiation therapy to enhance tumor immunotherapy: a novel application for an established modality
- (2019) Eric C. Ko et al. INTERNATIONAL JOURNAL OF RADIATION BIOLOGY
- A phase II clinical trial of pembrolizumab and selective androgen receptor modulator GTx-024 in patients with advanced androgen receptor-positive triple-negative breast cancer.
- (2019) Jin Sun Lee-Bitar et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab (pembro) with paclitaxel (taxol) or capecitabine (cape) as early treatment of metastatic triple-negative breast cancer (mTNBC).
- (2019) David B. Page et al. JOURNAL OF CLINICAL ONCOLOGY
- PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
- (2019) Constantia Pantelidou et al. Cancer Discovery
- A microparticle platform for STING-targeted immunotherapy enhances natural killer cell- and CD8+ T cell-mediated anti-tumor immunity
- (2019) Rebekah Watkins-Schulz et al. BIOMATERIALS
- CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth
- (2019) Ru Zhou et al. Frontiers in Immunology
- A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer
- (2019) Joanie Del Bano et al. Frontiers in Immunology
- Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer
- (2019) Shaveta Vinayak et al. JAMA Oncology
- PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review
- (2019) Planes-Laine et al. Cancers
- Tumor-infiltrating lymphocytes and CD8+ T cells predict survival of triple-negative breast cancer
- (2019) H. Vihervuori et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- LBA21KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC)
- (2019) J Cortés et al. ANNALS OF ONCOLOGY
- A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple‐negative breast cancer
- (2019) Alice Y. Ho et al. CANCER
- Current status and limitations of immunotherapy for breast cancer
- (2019) Yoshihisa Tokumaru et al. SURGERY
- Combination Immunotherapy with Cytotoxic T-Lymphocyte–Associated Antigen-4 and Programmed Death Protein-1 Inhibitors Prevents Postoperative Breast Tumor Recurrence and Metastasis
- (2019) Ting Sun et al. MOLECULAR CANCER THERAPEUTICS
- LXR-inverse agonism stimulates immune-mediated tumor destruction by enhancing CD8 T-cell activity in triple negative breast cancer
- (2019) Katherine J. Carpenter et al. Scientific Reports
- DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy
- (2018) Cynthia Bernier et al. ANTI-CANCER DRUGS
- The Immune Revolution: A Case for Priming, Not Checkpoint
- (2018) Robert H. Vonderheide CANCER CELL
- Abstract PD6-13: Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer
- (2018) SM Tolaney et al. CANCER RESEARCH
- Regulation and Function of the PD-L1 Checkpoint
- (2018) Chong Sun et al. IMMUNITY
- Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells
- (2018) Yali Han et al. Journal of Hematology & Oncology
- Immunotherapeutic interventions of Triple Negative Breast Cancer
- (2018) Zehuan Li et al. Journal of Translational Medicine
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- The Androgen Receptor in Breast Cancer
- (2018) Pia Giovannelli et al. Frontiers in Endocrinology
- Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
- (2018) S Adams et al. ANNALS OF ONCOLOGY
- Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
- (2018) S Adams et al. ANNALS OF ONCOLOGY
- Manipulation of the immune system for cancer defeat: a focus on the T cell inhibitory checkpoint molecules
- (2018) Paolo D`Arrigo et al. CURRENT MEDICINAL CHEMISTRY
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine
- (2018) Jake R. Conway et al. Genome Medicine
- Immunotherapy in triple-negative breast cancer
- (2017) Heather Katz et al. MEDICAL ONCOLOGY
- Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer
- (2017) Julia Tchou et al. Cancer Immunology Research
- PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
- (2017) Hashem O. Alsaab et al. Frontiers in Pharmacology
- A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling
- (2016) H. L. McArthur et al. CLINICAL CANCER RESEARCH
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
- (2016) Rita Nanda et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
- (2016) Vassiliki A. Boussiotis NEW ENGLAND JOURNAL OF MEDICINE
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
- (2016) Weiping Zou et al. Science Translational Medicine
- Combination cancer immunotherapy and new immunomodulatory targets
- (2015) Kathleen M. Mahoney et al. NATURE REVIEWS DRUG DISCOVERY
- Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer
- (2015) Simona Bramante et al. OncoImmunology
- Role of MAPK in oncolytic herpes viral therapy in triple-negative breast cancer
- (2014) S Gholami et al. CANCER GENE THERAPY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More